Search CHA Search
 

CHA is the leading organizer and facilitator of consortia and communities in the life sciences industry.  We reduce the costs of R&D by enabling multiple companies to cooperatively evaluate novel technologies, assess vendors and share ideas.  Our clients represent most of the largest biopharmaceutical companies in the world. 

Partnering with biopharma companies
We reduce R&D costs by bringing together biopharma leaders and top scientists to engage in knowledge-sharing at the pre-competitive level.

Partnering with technology providers
We improve marketing ROI by leveraging our robust industry networks to provide innovators with a unique platform to showcase their technologies. 


“CHA does a very professional and effective job facilitating peer-to-peer collaboration. The consortium approach is a very powerful model to evaluate new technologies."
- Dr. Stefan Mueller, Senior Toxicologist, Merck Serono Research

“Groups are remarkably smart, smarter even sometimes than the smartest people in them.”
- James Surowiecki, author of Wisdom of Crowds

Recently Completed Consortium and Projects

Evaluating Preclinical Cardio-Toxicity Assessment Tools
Pharmaceutical companies working together to explore emerging cardio-toxicity assessment practices and their potential to improve prediction of adverse effects on cardiac function caused by exposure to new chemical entities.
Assessing GLP Compliance & Quality Practices in China (by Jointly Funding Animal Safety Studies)
Pharmaceutical and biotechnology companies jointly funding animal safety studies at leading preclinical safety evaluation facilities in China so assess in a low risk manner if selected facilities can perform according to current global standards.

Upcoming Events

DSEC in the News
DSEC Recruits Pharmas For Early Drug Safety Testing . See full article by selecting title.
On-Demand: High Throughput Zebrafish Assays & Their Future Impact on Safety Decision Making
Originally, December 10 at 10:00 AM EDT. Click title for details.

On Demand Web Conferences

Current Strategies for Leveraging Preclinical Capabilities in China
Originally presented on June 24, 2008
Accelerating Technology Adoption in Pharma R&D
Originally presented on June 18, 2008
Adoption Process of Novel Technologies by Pharma in Preclinical R&D
Originally held March 13. Features an industry panel. Click the title to learn more.

Executive Summaries and Case Studies

Executive Summary: Confronting Major Safety issues of the 21st Century
Executive Summary from the Inaugural Drug Safety Executive Council (DSEC) Member Retreat
Chinese Preclininical Safety Data - Is the FDA Ready
Updates on Preclinical Safety Data in China - Article 2 in the Series (September 2008)
The Rise of China's Contract Research Sector: Evaluating Quality and Cost Benefits
Updates on Preclinical Safety Data in China - Article 1 in the Series (August 2008)